Clinical features of inherited coagulation disorders and study of newer treatment

Clinical profile of inherited coagulation disorders and assessment of efficacy of newer treatment modalities. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087118

Enrollment

Registered

2025-05-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D66- Hereditary factor VIII deficiency Health Condition 2: D67- Hereditary factor IX deficiency

Interventions

Intervention1: Emicizumab: Emicizumab will be given to hemophilia A patients and will be compared to on-demand treatment patients Intervention2: NIL: NIL Control Intervention1: on demand treatment: tr

Eligibility

Inclusion criteria

Inclusion criteria: Known cases of common inherited coagulation disorders (Hemophilia A, Hemophilia B, Von wilebrand Disease, other factor deficiencies) Subjects included will be patients with history of spontaneous bleeding in joints, mucocutaneous regions, following trivial trauma

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
To assess the decrease in number of bleeding episodes after the interventionTimepoint: 1 year	—

Secondary

Measure	Time frame
To assess efficacy of prophylactic treatment with on-demand in the management of inherited coagulation disorders.Timepoint: 12 months	—

Countries

India

Contacts

Public ContactAashita Kiran Naik

Goa Medical College and Hospital

drramnath.nevrekar@gmail.com9822295825

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026